• Share:

Publications 2009

Can't find the PDF you are looking for? Email Jessica Kohn for assistance.

 

Publications: 2009

 

1 - Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009 Jul 1;69(13):5312-20. Epub 2009 Jun 23.   PDF

2 - Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol. 2009 Jun;174(6):2367-77. Epub 2009 Apr 23.  PDF

3 - Herlyn M. Driving in the melanoma landscape. Exp Dermatol. 2009 Jun;18(6):506-8. Epub 2009 Mar 29.  PDF

4 - Villanueva, J., Herlyn, M. Melanoma. Encylopedia of Life Sciences.  Advanced Article. 2009. March 15. 1-9. PDF

5 - Greshock J., Nathanson K., Medina A., Ward MR, Herlyn M., Weber BL,  Zaks TZ. Distinct patterns of DNA copy number alterations associate  with BRAF mutations in melanomas and melanoma-derived cell lines.  Genes Chromosomes Cancer. 2009 May: 48(5): 419-428. PDF

6 - Vultur A., Herlyn M. Cracking the system: melanoma complexity demands  new therapeutic approaches. Pigment Cell Melanoma Res. 2009 Feb:  22(1): 4-5. PDF

7 - Santiago-Walker A, Li L, Haass NK, Herlyn M. Melanocytes: from morphology to application. Skin Pharmacol Physiol. 2009;22(2):114-21. Epub 2009 Feb 4.  PDF

8 - Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor aggressiveness. Cancer Biol Ther. 2009 Feb 30;8(4). [Epub ahead of print] No abstract available. PMID: 19182538 PDF

9 - Passegué E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nat Med. 2009 Jan;15(1):23. No abstract available. PMID: 19129778 PDF

10 - Smalley KS, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.Int J Cancer. 2009 Mar 15;124(6):1245-50.PMID: 19089923 PDF